Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women.
about
Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant womenIs protease inhibitors based antiretroviral therapy during pregnancy associated with an increased risk of preterm birth? Systematic review and a meta-analysisTransplacental exposure to AZT induces adverse neurochemical and behavioral effects in a mouse model: protection by L-acetylcarnitine.HIV/AIDS epidemiology, pathogenesis, prevention, and treatmentMaternal Lopinavir/Ritonavir Is Associated with Fewer Adverse Events in Infants than Nelfinavir or Atazanavir.Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infantsPregnancy outcomes and birth defects from an antiretroviral drug safety study of women in South Africa and Zambia.Pregnancy outcome in women infected with HIV-1 receiving combination antiretroviral therapy before versus after conceptionHIV-exposed infants: rethinking care for a lifelong condition.Antiretroviral drugs for preventing mother-to-child transmission of HIV in sub-Saharan Africa: balancing efficacy and infant toxicity.Prenatal protease inhibitor use and risk of preterm birth among HIV-infected women initiating antiretroviral drugs during pregnancy.Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C.Neurodevelopment and in utero antiretroviral exposure of HIV-exposed uninfected infants.Zidovudine exposure in HIV-1 infected Tanzanian women increases mitochondrial DNA levels in placenta and umbilical cordsIncidence of and socio-biologic risk factors for spontaneous preterm birth in HIV positive Nigerian women.Effects of in utero antiretroviral exposure on longitudinal growth of HIV-exposed uninfected infants in BotswanaIncreased risk of preterm delivery among HIV-infected women randomized to protease versus nucleoside reverse transcriptase inhibitor-based HAART during pregnancyLow birth weight in perinatally HIV-exposed uninfected infants: observations in urban settings in Cameroon.Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study).Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population.Prevention of mother-to-child transmission of HIV type 1: the role of neonatal and infant prophylaxis.Antiretroviral treatment of maternal HIV infectionAntiretroviral therapy and mother-to-child transmission of HIV-1.Neurologic Outcomes in HIV-Exposed/Uninfected Infants Exposed to Antiretroviral Drugs During Pregnancy in Latin America and the Caribbean.German-Austrian recommendations for HIV1-therapy in pregnancy and in HIV1-exposed newborn, update 2008A trigger-based design for evaluating the safety of in utero antiretroviral exposure in uninfected children of human immunodeficiency virus-infected mothersRapid HIV testing. Wait time reduced from days to minutes.Insufficient antiretroviral therapy in pregnancy: missed opportunities for prevention of mother-to-child transmission of HIV in Europe.Pharmacotherapy of pediatric HIV infectionAntiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.Mitochondrial disease in the offspring as a result of antiretroviral therapy.Treating HIV during pregnancy: an update on safety issues.High levels of zidovudine (AZT) and its intracellular phosphate metabolites in AZT- and AZT-lamivudine-treated newborns of human immunodeficiency virus-infected mothersLaboratory Abnormalities Among HIV-Exposed, Uninfected Infants: IMPAACT Protocol P1025Routine antenatal HIV testing: the responses and perceptions of pregnant women and the viability of informed consent. A qualitative studySafety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.Maternal HIV infection and other factors associated with growth outcomes of HIV-uninfected infants in Entebbe, UgandaProphylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007.Safety of protease inhibitors in HIV-infected pregnant women.
P2860
Q24236763-52CED1A6-C264-455E-9C97-7BE5A07B1485Q28066290-75ED9A13-C9D3-45C6-9CA0-FFD2A1D985CCQ28486041-1D6E66C8-24E8-4FB2-BD2B-EF3CFA51DC62Q30356074-69DDAFA5-EEFF-41B5-9DEF-10C7A3D40FD7Q33431825-C2FAB8A5-9FEF-4B0A-A12D-47649FF86F2EQ33747993-3D48734E-B702-416E-BCB7-AD88B07A8361Q33754231-B8E0CA5D-2794-41EF-8EC9-CFAA25F63D31Q33830084-8415C43C-C5B9-43A0-8861-626EDF28ED50Q33871174-C21191FE-9187-4C18-AD65-C73907FAB8E0Q33897042-4591F9E5-DF59-4B9D-9FDA-6CD7907F7AECQ34158407-D67A9FEE-DE77-4133-B34B-808013F88760Q34170220-199B9C5A-709E-48B8-BC62-3DA02532AB1AQ34181048-77F15644-2B61-4666-BDCF-B2BA9511BC4CQ34358732-0E47F8ED-33B6-4E80-99A4-E7E3AB5E1386Q34408889-0B2AAEC1-6163-46A6-A5CC-116F94E2C613Q34500824-1D9E35FB-9255-4AA5-B2FF-3A5F1C2E42FFQ35129403-9F943CE0-AB94-45AE-A8AD-7A69BF2D846AQ35140240-82B31949-F104-470C-8B99-B0FFD8DF3034Q35327135-058CFEF2-AEFD-49DE-9DA0-9B2C8948C562Q35626381-7D4C4259-F4EB-4CC1-AE75-FD65335FB66AQ35738687-37DF26F9-1875-401D-9818-3BE207DE93E5Q35751105-5ABD9F29-540E-4E7C-8809-ADDFA410DD9CQ35826189-335C6255-5637-4F2C-8E94-3F9C21F9CC9EQ35917533-88B1B1D5-1A15-46B5-A58B-1B7EA78F4221Q35924264-69C73C73-FE98-4044-BE64-4273F130799CQ35960319-7C1ED134-93E4-439C-85A8-B9FF2F022D4BQ36077016-30ED33E0-46CE-44B2-80CC-097542D75E52Q36077037-5101E59F-E916-436C-987C-E062D4D4A526Q36193260-EF91290F-CEFF-4B7E-BA00-E09E98A6C212Q36301325-B3E9BEED-464B-4EA2-9841-ED6F7C475A3FQ36438846-5A0A8BF6-1486-4D51-8A46-96F0DC400198Q36446890-A33B343E-5F63-4113-B076-1EC43C5B375BQ36497045-8545A29F-D942-4F0B-8A89-E06904997DC2Q36744874-571C6AE4-16F1-4A84-8043-BF25CF5FF346Q36851168-B7D30B50-BF60-4124-8982-57AFF2BECD88Q37005259-7714F5BD-2BF6-45A7-9F58-EA94D0C5C8A8Q37045192-898DDDD8-C6CC-4B59-882F-50F84514DA04Q37068923-BB3FAACC-A200-4813-964E-5E033098026FQ37201577-F5A3F3BF-0922-42F2-A17E-14763498C9E6Q37215994-336A4022-23F8-473E-B5CB-4CE5F1D511BC
P2860
Exposure to antiretroviral therapy in utero or early life: the health of uninfected children born to HIV-infected women.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Exposure to antiretroviral the ...... en born to HIV-infected women.
@en
Exposure to antiretroviral the ...... en born to HIV-infected women.
@nl
type
label
Exposure to antiretroviral the ...... en born to HIV-infected women.
@en
Exposure to antiretroviral the ...... en born to HIV-infected women.
@nl
prefLabel
Exposure to antiretroviral the ...... en born to HIV-infected women.
@en
Exposure to antiretroviral the ...... en born to HIV-infected women.
@nl
P1476
Exposure to antiretroviral the ...... en born to HIV-infected women.
@en
P304
P356
10.1097/00126334-200304010-00006
P407
P577
2003-04-01T00:00:00Z